Fexinidazole: First Global Approval

@article{Deeks2019FexinidazoleFG,
  title={Fexinidazole: First Global Approval},
  author={Emma Deeks},
  journal={Drugs},
  year={2019},
  volume={79},
  pages={215-220}
}
Fexinidazole Winthrop (hereafter referred to as fexinidazole) is a DNA synthesis inhibitor developed by the Drugs for Neglected Diseases initiative (DNDi), in collaboration with Sanofi, for the oral treatment of human African trypanosomiasis (HAT) [commonly known as ‘sleeping sickness’] and Chagas’ disease. The drug is a 5-nitroimidazole derivative first discovered by Hoechst AG (now part of Sanofi) and was identified by the DNDi in 2005 as having activity against Trypanosoma brucei gambiense… Expand
Innovative Partnerships for the Elimination of Human African Trypanosomiasis and the Development of Fexinidazole
TLDR
The long-standing collaboration between the WHO, Sanofi and the Drugs for Neglected Diseases initiative was instrumental for achieving the control and treatment development goals in HAT, whilst at the same time ensuring that efforts were led by national authorities and control programs to leave a legacy of highly trained healthcare workers and improved research and health infrastructure. Expand
Evidence of Pyrimethamine and Cycloguanil Analogues as Dual Inhibitors of Trypanosoma brucei Pteridine Reductase and Dihydrofolate Reductase
TLDR
A small library of CYC analogues is explored to understand how their substitution pattern affects the inhibition of both TbPTR1 and TbDHFR, and it is shown that the known drug pyrimethamine (PYR) effectively targets both enzymes, also unveiling its binding mode to TbpTR1. Expand
Lipophilic Guanylhydrazone Analogues As Promising Trypanocidal Agents: An Extended SAR Study.
TLDR
The n-decyl C1-substituted compound G8 (R = C10H21) proved to be the most potent adamantane derivative against T. brucei with activity in nanomolar range (EC50=90 nM), illustrating the synergistic effect of the lipophilic character of the C1 side chain and guanylhydrazone moiety on trypanocidal activity. Expand
Emerging agents for the treatment of Chagas disease: what is in the preclinical and clinical development pipeline?
TLDR
From state-of-the-art in vitro and in vivo assays based on genetically engineered parasites that have allowed high throughput screenings of large chemical collections, to the unfulfilled requirement of having treatment-response biomarkers for the clinical evaluation of drugs, the most promising pre-clinical hits and the landscape of clinical trials with new drugs or new regimens of existing ones are described. Expand
Phenotypic Drug Discovery for Human African Trypanosomiasis: A Powerful Approach
TLDR
This research demonstrates the power of the phenotypic drug discovery approach for neglected tropical diseases by screening a library of 700,000 small molecules for inhibitors of Trypanosoma brucei growth without knowledge of the mechanism of action for the compounds. Expand
6-Methyl-7-deazapurine nucleoside analogues as broad-spectrum antikinetoplastid agents
TLDR
This study assessed the in vitro activity profile of 7-modified 6-methyl tubercidin derivatives against Trypanosoma cruzi, Leishmania infantum, Trypano-Brucei brucei and T. b. Expand
Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.
TLDR
Comparative appraisal of one preferred lead in a chronic infection mouse model, monitored by highly sensitive bioluminescence imaging, provided the first definitive evidence of (partial) curative efficacy with this promising nitroimidazooxazine class. Expand
Novel nitroimidazole derivatives evaluated for their trypanocidal, cytotoxic, and genotoxic activities.
TLDR
The design strategy was capable of generating novel and active Bnz analogs and showed the importance of the size and π-π interactions between the nitroimidazole and the cofactor of T.cruzi-nitroreductase (TcNTR). Expand
New Pd-Fe ferrocenyl antiparasitic compounds with bioactive 8-hydroxyquinoline ligands: a comparative study with their Pt-Fe analogues.
TLDR
Five new Pd-Fe heterobimetallic compounds, including 8-hydroxyquinolyl derivatives HL1-HL5 as bioactive ligands and dppf = 1,1'-bis(diphenylphosphino)ferrocene as the organometallic co-ligand, were synthesized and fully characterized in the solid state and in solution. Expand
Combination therapy using nitro compounds improves the efficacy of experimental Chagas disease treatment
TLDR
The objective of this work is to assess the effects of treatment with nitro drugs combinations using benznidazole or nifurtimox plus the sulfone metabolite of fexinidazoles (fex-SFN) in vitro and in vivo on Trypanosoma cruzi infection. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 16 REFERENCES
Fexinidazole – A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness
TLDR
Fexinidazole is shown to be a short-course, safe and effective oral treatment curing both acute and chronic HAT and that could be implemented at the primary health care level and the results of the preclinical pharmacological and safety studies indicate that fexinidrazole is a safe andeffective oral drug candidate with no untoward effects that would preclude evaluation in man. Expand
Antitrypanosomal Activity of Fexinidazole, a New Oral Nitroimidazole Drug Candidate for Treatment of Sleeping Sickness
TLDR
In vitro and in vivo antitrypanosomal activities of fexinidazole and its two principal metabolites provide evidence that the compound has the potential to be an effective oral treatment for both the T. b. Expand
Fexinidazole: A Potential New Drug Candidate for Chagas Disease
TLDR
Fexinidazoles is an effective oral treatment of acute and chronic experimental CD caused by benznidazole-susceptible, partially resistant, and resistant T. cruzi strains, although parasite eradication was not achieved in all treated animals at the tested doses. Expand
Management of trypanosomiasis and leishmaniasis
TLDR
Clinical studies with benznidazole, a drug previously recommended only for acute stage treatment, are close to completion to determine the effectiveness in the treatment of early chronic and indeterminate Chagas disease. Expand
The Anti-Trypanosome Drug Fexinidazole Shows Potential for Treating Visceral Leishmaniasis
TLDR
Fexinidazole, a drug currently in phase 1 clinical trials for treating African trypanosomiasis, shows promise for treating visceral leishmaniasis, and is comparable to that of drugs currently in clinical use against this deadly tropical disease. Expand
Genotoxicity profile of fexinidazole--a drug candidate in clinical development for human African trypanomiasis (sleeping sickness).
TLDR
Fexinidazole does not pose a genotoxic hazard to patients and represents a promising drug candidate for HAT, and is expected to enter Phase II clinical trials in 2012. Expand
Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial
TLDR
The findings show that oral fexinidazole is effective and safe for the treatment of Tpanosoma brucei gambiense infection compared with nifurtimox eflornithine combination therapy in patients with late-stage g-HAT. Expand
Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasis.
TLDR
The recently validated bioluminescence imaging model was used to assess the dose and rate of kill effect of fexinidazole in infected mice, and the dose-dependent effect of Fexinodazole on trypanosome infection, and Pharmacokinetics of feXinidrazole in plasma and central nervous system compartments were similar in both infected and uninfected mice. Expand
Evaluation of trypanocidal drugs used for human African trypanosomosis against Trypanosoma lewisi
TLDR
In vitro evaluation of drugs and fexinidazole, a new oral drug candidate, have been performed against T. lewisi in comparison with T. brucei gambiense, finding all have comparable activities against the two parasites. Expand
Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage
TLDR
A systematic study of nitroheterocyclic drug efficacy using highly sensitive bioluminescence imaging of murine infections finds both drugs are more effective at curing chronic infections, judged by treatment duration and therapeutic dose. Expand
...
1
2
...